228 related articles for article (PubMed ID: 33749164)
1. Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States.
Boettiger DC; Newall AT; Phillips A; Bendavid E; Law MG; Ryom L; Reiss P; Mocroft A; Bonnet F; Weber R; El-Sadr W; d'Arminio Monforte A; de Wit S; Pradier C; Hatleberg CI; Lundgren J; Sabin C; Kahn JG; Kazi DS
J Int AIDS Soc; 2021 Mar; 24(3):e25690. PubMed ID: 33749164
[TBL] [Abstract][Full Text] [Related]
2. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis.
Boettiger DC; Newall AT; Chattranukulchai P; Chaiwarith R; Khusuwan S; Avihingsanon A; Phillips A; Bendavid E; Law MG; Kahn JG; Ross J; Bautista-Arredondo S; Kiertiburanakul S
J Int AIDS Soc; 2020 Jun; 23 Suppl 1(Suppl 1):e25494. PubMed ID: 32562359
[TBL] [Abstract][Full Text] [Related]
3. Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis.
Boettiger DC; Chattranukulchai P; Avihingsanon A; Chaiwarith R; Khusuwan S; Law MG; Ross J; Kiertiburanakul S
PLoS One; 2021; 16(9):e0256926. PubMed ID: 34499685
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
[TBL] [Abstract][Full Text] [Related]
5. Impact of China's Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease.
Wang M; Liu J; Bellows BK; Qi Y; Sun J; Liu J; Moran AE; Zhao D
Glob Heart; 2020 Jun; 15(1):43. PubMed ID: 32923337
[TBL] [Abstract][Full Text] [Related]
6. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
[TBL] [Abstract][Full Text] [Related]
7. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.
Erickson KF; Japa S; Owens DK; Chertow GM; Garber AM; Goldhaber-Fiebert JD
J Am Coll Cardiol; 2013 Mar; 61(12):1250-8. PubMed ID: 23500327
[TBL] [Abstract][Full Text] [Related]
10. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study.
McConnachie A; Walker A; Robertson M; Marchbank L; Peacock J; Packard CJ; Cobbe SM; Ford I
Eur Heart J; 2014 Feb; 35(5):290-8. PubMed ID: 23839541
[TBL] [Abstract][Full Text] [Related]
11. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.
Pletcher MJ; Lazar L; Bibbins-Domingo K; Moran A; Rodondi N; Coxson P; Lightwood J; Williams L; Goldman L
Ann Intern Med; 2009 Feb; 150(4):243-54. PubMed ID: 19221376
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals.
Spahillari A; Zhu J; Ferket BS; Hunink MGM; Carr JJ; Terry JG; Nelson C; Mwasongwe S; Mentz RJ; O'Brien EC; Correa A; Shah RV; Murthy VL; Pandya A
JAMA Cardiol; 2020 Aug; 5(8):871-880. PubMed ID: 32401264
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis.
Jarmul J; Pletcher MJ; Hassmiller Lich K; Wheeler SB; Weinberger M; Avery CL; Jonas DE; Earnshaw S; Pignone M
Circ Cardiovasc Qual Outcomes; 2018 Apr; 11(4):e004171. PubMed ID: 29650716
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Michaeli DT; Michaeli JC; Boch T; Michaeli T
Clin Drug Investig; 2022 Aug; 42(8):643-656. PubMed ID: 35819632
[TBL] [Abstract][Full Text] [Related]
15. Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease.
Kohli-Lynch CN; Lewsey J; Boyd KA; French DD; Jordan N; Moran AE; Sattar N; Preiss D; Briggs AH
Circulation; 2022 Apr; 145(17):1312-1323. PubMed ID: 35249370
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes.
Li T; Wan X; Ma J; Wu B
Adv Ther; 2018 Dec; 35(12):2214-2223. PubMed ID: 30390239
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction.
Ademi Z; Ofori-Asenso R; Zomer E; Owen A; Liew D
Eur J Prev Cardiol; 2021 Jul; 28(8):897-904. PubMed ID: 34298556
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.
de Vries FM; Denig P; Visser ST; Hak E; Postma MJ
Value Health; 2014 Mar; 17(2):223-30. PubMed ID: 24636380
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I; Kent S; Herrington W; Emberson J; Haynes R; Reith C; Collins R; Landray MJ; Gray A; Baigent C; Mihaylova B;
Kidney Int; 2019 Jul; 96(1):170-179. PubMed ID: 31005271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
